INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,463 | -26.0% | 18,418 | -55.8% | 0.00% | 0.0% |
| Q2 2023 | $461,158 | -19.2% | 41,696 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $570,585 | +0.4% | 42,486 | -7.4% | 0.00% | 0.0% |
| Q4 2022 | $568,470 | +215.8% | 45,899 | +255.0% | 0.00% | – |
| Q3 2022 | $180,000 | -2.2% | 12,931 | -2.7% | 0.00% | – |
| Q2 2022 | $184,000 | -17.1% | 13,293 | -3.0% | 0.00% | – |
| Q1 2022 | $222,000 | -12.9% | 13,702 | -12.5% | 0.00% | – |
| Q4 2021 | $255,000 | +8.1% | 15,662 | -1.5% | 0.00% | – |
| Q3 2021 | $236,000 | -27.2% | 15,901 | -2.3% | 0.00% | -100.0% |
| Q2 2021 | $324,000 | -68.3% | 16,278 | -63.3% | 0.00% | -50.0% |
| Q1 2021 | $1,023,000 | -23.8% | 44,328 | -18.5% | 0.00% | -50.0% |
| Q4 2020 | $1,343,000 | -56.5% | 54,405 | -26.9% | 0.00% | -55.6% |
| Q3 2020 | $3,090,000 | -14.5% | 74,398 | -1.3% | 0.01% | -25.0% |
| Q2 2020 | $3,612,000 | -23.7% | 75,398 | +0.4% | 0.01% | -36.8% |
| Q1 2020 | $4,732,000 | – | 75,135 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |